Casi pharmaceuticals enteres into sublicense agreement with tianshi pharmaceuticals for anti-cd38 monoclonal antibody (mab) cid-103 in autoimmune field

~ casi to receive upfront payment of $10 million in two instalments ~ ~ casi through its wholly-owned prc subsidiary, will hold 15% equity of tianshi ~ rockville, md. and beijing, may 24, 2022 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi), a u.s. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the signing of a sublicense agreement with beijing tianshi tongda pharmaceuticals technology co., ltd.
CASI Ratings Summary
CASI Quant Ranking